Tetrac-conjugated polymersomes for integrin-targeted delivery of camptothecin to colon adenocarcinoma in vitro and in vivo.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier/North-Holland Biomedical Press Country of Publication: Netherlands NLM ID: 7804127 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3476 (Electronic) Linking ISSN: 03785173 NLM ISO Abbreviation: Int J Pharm Subsets: MEDLINE
    • Publication Information:
      Original Publication: Amsterdam, Elsevier/North-Holland Biomedical Press.
    • Subject Terms:
      Drug Delivery Systems*; Adenocarcinoma/*drug therapy ; Camptothecin/*administration & dosage ; Colonic Neoplasms/*drug therapy ; Thyroxine/*analogs & derivatives; Animals ; Cell Line, Tumor ; Female ; HT29 Cells ; Humans ; Integrin alphaVbeta3/metabolism ; Mice ; Mice, Inbred BALB C ; Thyroxine/chemistry
    • Abstract:
      In this study, we prepared tetraiodothyroacetic acid (tetrac) conjugated PEG-PLGA polymersomes for the targeted delivery of camptothecin to colon adenocarcinoma. Tetrac, which binds to integrin α v β 3 with high affinity and specificity, was covalently conjugated to the surface of the PEGylated polymersomal formulation of camptothecin (CPT). The hydrodynamic and morphological properties of the prepared system were evaluated using TEM (transmission electron microscopy), SEM (scanning electron microscopy) and DLS (dynamic light scattering) experiments. Camptothecin was encapsulated in the polymersomal system with encapsulation efficiency and loading content of 84±10.12 and 4.2±0.82, respectively. The in vitro release profile of camptothecin from the polymersomal formulation revealed the sustained release pattern. In vitro cytotoxicity experiments confirmed that the tetrac-conjugated camptothecin loaded-polymersomes had higher cellular toxicity towards integrin-overexpressed HT29 and C26 colorectal cancer cells than integrin-negative CHO cell line. The in vivo tumor inhibitory effect of tetrac-conjugated camptothecin loaded-polymersomes demonstrated an enhanced therapeutic index of integrin targeted polymersomal formulation over both non-targeted polymersomal formulation and free camptothecin in C26 tumor bearing mice. The obtained results demonstrated that the prepared tetrac-conjugated polymersomes were able to control the release of camptothecin, and significantly increase the therapeutic index of compthotecin. This study demonstrates the versatility of integrin-targeted tetrac-conjugated PEG-PLGA polymersomal formulation as an anti-cancer nano-pharmaceutical platform.
      (Copyright © 2017 Elsevier B.V. All rights reserved.)
    • Contributed Indexing:
      Keywords: Camptothecin; Colon adenocarcinoma; PEG-PLGA; Polymersomes; Tetrac
    • Accession Number:
      0 (Integrin alphaVbeta3)
      PA7UX1FFYQ (tetraiodothyroacetic acid)
      Q51BO43MG4 (Thyroxine)
      XT3Z54Z28A (Camptothecin)
    • Publication Date:
      Date Created: 20170923 Date Completed: 20180110 Latest Revision: 20181202
    • Publication Date:
      20231215
    • Accession Number:
      10.1016/j.ijpharm.2017.09.039
    • Accession Number:
      28935257